검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent)) GlaxoSmithKline·HIV Infections ORR 94.99% |
|---|---|
Overview Program | Pneumococcal Vaccine, Polyvalent (23-valent) |
Overview Company | GlaxoSmithKline |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | PCV13/PPSV23 Co-vaccination versus PPSV23 Monotherapy for the Prevention of Pneumococcal Infections: A Systematic Review and Meta-analysis.. The 23-valent pneumococcal polysaccharide (PPSV23) and 13-valent pneumococcal conjugate (PCV13) vaccines are available for the prevention of infections caused by Streptococcus pneumoniae. This systematic review and meta-analysis evaluated the immunogenicity a… |
Clinical Primary efficacy | ORR 94.99% |
Clinical ORR | 94.99% |
Clinical Result source | ClinicalTrials.gov NCT01341639 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent)) GlaxoSmithKline·HIV Infections ORR 94.99% |
|---|---|
Overview Program | Pneumococcal Vaccine, Polyvalent (23-valent) |
Overview Company | GlaxoSmithKline |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | PCV13/PPSV23 Co-vaccination versus PPSV23 Monotherapy for the Prevention of Pneumococcal Infections: A Systematic Review and Meta-analysis.. The 23-valent pneumococcal polysaccharide (PPSV23) and 13-valent pneumococcal conjugate (PCV13) vaccines are available for the prevention of infections caused by Streptococcus pneumoniae. This systematic review and meta-analysis evaluated the immunogenicity a… |
Clinical Primary efficacy | ORR 94.99% |
Clinical ORR | 94.99% |
Clinical Result source | ClinicalTrials.gov NCT01341639 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교